Natural killer cells as indispensable players and therapeutic targets in autoimmunity

Autoimmunity

Volumn 44, Issue 1, 2011, Pages 3-10

  Shi, Fu Dong ^a,b   Zhou, Qinghua ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Autoimmune disease; Autoimmunity; Multiple sclerosis; NK cells innate immune system

Indexed keywords

DACLIZUMAB;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; IMMUNOTHERAPY; INFLAMMATORY DISEASE; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NATURAL KILLER CELL; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASES; AUTOIMMUNITY; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL;

EID: 78751473203     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916931003782122     Document Type: Review

References (50)

1. Shi F, Ransohoff R, editors. Nature killer cells in the central nervous system. Natural killer cells: Basic science and clinical application. In: Michael T. Lotze, AngusW. Thomson, editors. London: Academic Press, 2010.
2. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu Rev Immunol 1999;17: 189-220.
3. Hughes T, Becknell B, McClory S, Briercheck E, Freud AG, Zhang X, Mao H, Nuovo G, Yu J, Caligiuri MA. Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood 2009;113: 4008-4010.
4. Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, Grogan JL, Fibbe WE, Cornelissen JJ, Spits H. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol 2009;10:66-74.
5. Flodstrom M, Maday A, Balakrishna D, Cleary MM, Yoshimura A, Sarvetnick N. Target cell defense prevents the development of diabetes after viral infection. Nat Immunol 2002;3:373-382.
6. Shi FD, Van Kaer L. Reciprocal regulation between natural killer cells and autoreactive T cells. Nat Rev 2006;6: 751-760. (Pubitemid 44453461)
7. Zimmer J, Bausinger H, de la Salle H. Autoimmunity mediated by innate immune effector cells. Trends Immunol 2001;22:300-301.
8. Moins-Teisserenc HT, Gadola SD, Cella M, Dunbar PR, Exley A, Blake N, Baykal C, Lambert J, Bigliardi P, Willemsen M, Jones M, Buechner S, Colonna M, Gross WL, Cerundolo V. Association of a syndrome resemblingWegeners granulomatosis with low surface expression of HLA class-I molecules. Lancet 1999;354:1598-1603.
9. La Cava A, Van Kaer L, Fu Dong S. CD4+CD25+ Tregs and NKT cells: Regulators regulating regulators. Trends Immunol 2006;27:322-327.
10. Liu R, Van Kaer L, La Cava A, Price M, Campagnolo DI, Collins M, Young DA, Vollmer TL, Shi FD. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J Immunol 2006;176:5247-5254.
11. Shi FD, Wang HB, Li H, Hong S, Taniguchi M, Link H, Van Kaer L, Ljunggren HG. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 2000;1:245-251.
12. Dotta F, Fondelli C, Falorni A. Can NK cells be a therapeutic target in human type 1 diabetes? Eur J Immunol 2008;38: 2961-2963.
13. Feuerer M, Shen Y, Littman DR, Benoist C, Mathis D. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 2009;31:654-664.
14. Poirot L, Benoist C, Mathis D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Acad Sci USA 2004;101: 8102-8107.
15. Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, Lanier LL. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 2004; 20:757-767.
16. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009;155:173-181.
17. Rodacki M, Svoren B, Butty V, Besse W, Laffel L, Benoist C, MathisD. Altered natural killer cells in type 1 diabetic patients. Diabetes 2007;56:177-185.
18. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Sanz M, Exley M, Wilson B, Porcelli S, Maclaren N. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002;109:131-140.
19. Nilsson N, Bremell T, Tarkowski A, Carlsten H. Protective role of NK1.1+ cells in experimental Staphylococcus aureus arthritis. Clin Exp Immunol 1999;117:63-69.
20. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005;7:R30-R37.
21. Green MR, Kennell AS, Larche MJ, SeifertMH, IsenbergDA, Salaman MR. Natural killer cell activity in families of patients with systemic lupus erythematosus: Demonstration of a killing defect in patients. Clin Exp Immunol 2005;141:165-173.
22. Nedvetzki S, Sowinski S, Eagle RA, Harris J, Vely F, Pende D, Trowsdale J, Vivier E, Gordon S, Davis DM. Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood 2007;109: 3776-3785.
23. Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004;173:6418-6426.
24. Zhang AL, Colmenero P, Purath U, Teixeira de Matos C, Hueber W, Klareskog L, Tarner IH, Engleman EG, Soderstrom K. Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood 2007;110: 2484-2493.
25. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 1997;186: 1677-1687.
26. HuangDF, ShiD, Jung S, PienGC,Wang J, Salazar-MatherTP, He TT, Weaver JT, Ljunggren HG, Biron CA, Littman DR, Ransohoff RM. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 2006;20:896-905.
27. Takahashi K, Miyake S, Kondo T, Terao K, Hatakenaka M, Hashimoto S, Yamamura T. Natural killer type 2 bias in remission of multiple sclerosis. J Clin Invest 2001;107: R23-R29.
28. Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW. A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J Neuroimmunol 1998;86:123-133.
29. Sand KL, Knudsen E, Rolin J, Al-Falahi Y, Maghazachi AA. Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell Mol Life Sci 2009; 66:1446-1456.
30. Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW. Natural killer cells in relapsing-remitting MS: Effect of treatment with interferon beta-1B. Neurology 1999;52:351-359.
31. Vandenbark AA, Huan J, Agotsch M, La Tocha D, Goelz S, Offner H, Lanker S, Bourdette D. Interferon-beta-1a treatment increases CD56(bright) natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 2009;215:125-128.
32. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006;103:5941-5946.
33. Li Z, Lim WK, Mahesh SP, Liu B, Nussenblatt RB. Cutting edge: In vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol 2005;174: 5187-5191.
34. Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009;66:483-489.
35. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24:677-688.
36. McGeachy MJ, Cua DJ. Th17 cell differentiation: The long and winding road. Immunity 2008;28:445-453.
37. Dong C. TH17 cells in development: An updated view of their molecular identity and genetic programming. Nat Rev 2008;8: 337-348.
38. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8: 345-350.
39. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, Tian Q, Dong C. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009;30:576-587.
40. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WK, McClanahan TK, OShea JJ, Cua DJ. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009;10:314-324.
41. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006;177:566-573.
42. Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting endogenous myelin peptides preferentially polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol 2007;8:172-180.
43. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, Gold R. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005;237:123-130.
44. Haak S, Croxford AL, Kreymborg K, Heppner FL, Pouly S, Becher B, Waisman A. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 2009;119:61-69.
45. OGarra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998;8: 275-283.
46. Romagnani S. Induction of TH1 and TH2 responses: A key role for the natural immune response? Immunol Today 1992; 13:379-381.
47. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004;5:1260-1265.
48. Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol 2005;6:600-607.
49. Chambers BJ, Salcedo M, Ljunggren HG. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 1996;5:311-317.
50. Xu W, Fazekas G, Hara H, Tabira T. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005;163:24-30.